LAKE FOREST, Ill., July 13 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced a study showing how the TheraDoc™ clinical surveillance system helped clinicians at Memorial Hospital Miramar reduce catheter-related infections, which correlated with an increase in infection-control interventions. The hospital, which used TheraDoc to electronically track the number of interventions and catheters removed, as well as infection rates, is reporting the results in a poster presentation at the 2010 Association for Professionals in Infection Control and Epidemiology (APIC) annual conference in New Orleans July 11–15.
Memorial Hospital Miramar, a 178-bed facility in South Florida, began using the TheraDoc Infection Control Assistant™ in 2008 to electronically record requests to remove urinary and central line catheters, and to document catheter-related urinary tract and bloodstream infections. Intervention requests were made by the hospital's infection preventionist, who attended daily rounds with the medical teams and often suggested the removal of urinary and central line catheters to help reduce infection risk. Months with more interventions were associated with fewer catheter-related infections, providing data to support infection-prevention efforts.
Catheter-associated infections are a significant problem for hospitals. Urinary tract infections (UTIs) account for 40 percent of the healthcare-acquired infections (HAIs) in the United States,(1) and 250,000 to 500,000 catheter-associated bloodstream infections (CABIs) occur in the nation each year. In addition to improving patient safety, avoiding these infections can result in significant cost savings for hospitals -- costs for each UTI and CABI are estimated at $600 and up to $29,000, respectively.(2)
According to Alex Chavez, C.I.C., infection-control practitioner at Memorial Hospital Miramar, preventing catheter-related infections is a focus for infection preventionists, but manually documenting and assessing the impact of interventions on infection rates can be challenging. When Chavez learned that the hospital was using TheraDoc to assess pharmacy interventions, he realized that the technology could do the same for infection prevention.
"The ability to electronically document interventions and then tie them to reduced infection rates is critical," Chavez said. "TheraDoc helps us quantify the value of infection preventionists in improving patient care and demonstrates the importance of interactions between infection preventionists and clinical staff."
Memorial Hospital Miramar, part of Memorial Healthcare System, has been using TheraDoc for infection prevention since 2008. TheraDoc automates the collection and analysis of clinical data from a range of sources within the hospital and alerts caregivers to clinically significant changes in patients' conditions that need to be addressed. The software also helps coordinate communication among care teams and hospital executives, and facilitates reporting to public health officials and quality organizations.
"Memorial Healthcare's innovative use of the TheraDoc clinical surveillance platform spans many areas of patient care -- from documenting infection prevention and pharmacy activities and meeting pediatric asthma core quality measures, to tracking H1N1 influenza cases," said Stanley Pestotnik, M.S., R.Ph., general manager, TheraDoc. "Its success with these initiatives illustrates the versatility of the TheraDoc platform to help clinicians quickly address quality and patient safety challenges that hospitals face every day."
Other abstracts related to TheraDoc being presented at the 2010 APIC meeting include:
With the patented TheraDoc Expert System Platform™ as the engine, the Infection Control Assistant complements several hospital surveillance modules powered by TheraDoc, including the ADE Assistant™, Clinical Alerts Assistant™, Antibiotic Assistant™ and the company's newest TheraDoc module, the Anticoagulation Assistant™. With 1.7 million HAIs occurring annually, clinicians at the Johns Hopkins Medical Institutions used Infection Control Assistant to help reduce HAI-confirmation time by 50 percent while achieving 98 percent accuracy of infection identification.(3),(4) For more information about the TheraDoc platform, visit www.theradoc.com.
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at www.hospira.com.
(1) Johnson J, Kuskowski M, Wilt T. Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients. Ann Intern Med. Jan. 17 2006;144:116–126.
(2) Weinstein R. An evidence-based approach to the prevention of central line-associated bloodstream infections in hospitalized patients. http://cme.medscape.com/viewarticle/705882. Accessed May 19, 2010.
(3) Klevens RM, Edwards JR, et. al. Estimating health care-associated infections and deaths in U.S. hospitals. Public Health Reports: Volume 122, March–April 2007. http://www.cdc.gov/ncidod/dhqp/pdf/Scott_CostPaper.pdf Accessed Nov. 4, 2009.
(4) Xiaoyan S, Mackie K, et. al. Benefits of using TheraDoc to assist in surveillance for central line associated nomsocomial bloodstream Infections (CA-BSIs). 17th Annual Scientific Session. SHEA, 2006.
|SOURCE Hospira, Inc.|
Copyright©2010 PR Newswire.
All rights reserved